June 17 (Reuters) - Verve Therapeutics Inc VERV.O:
LILLY TO ACQUIRE VERVE THERAPEUTICS TO ADVANCE ONE-TIME TREATMENTS FOR PEOPLE WITH HIGH CARDIOVASCULAR RISK
ELI LILLY - PROPOSED DEAL FOR PURCHASE PRICE OF $10.50 PER SHARE IN CASH
ELI LILLY - PROPOSED DEAL FOR A TOTAL POTENTIAL CONSIDERATION OF UP TO $13.50 PER SHARE IN CASH WITHOUT INTEREST
ELI LILLY - TRANSACTION IS NOT SUBJECT TO ANY FINANCING CONDITION
ELI LILLY: CVR HOLDERS WOULD BE ENTITLED TO GET CONTINGENT PAYMENT UPON FIRST PATIENT BEING DOSED WITH VERVE-102 FOR ASCVD IN U.S. PHASE 3 TRIAL
Source text: ID:nPn5VQH2Fa
Further company coverage: VERV.O
((Reuters.Briefs@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。